Cargando…
Feasibility of urinary microRNA detection in breast cancer patients and its potential as an innovative non-invasive biomarker
BACKGROUND: Since recent studies revealed the feasibility to detect blood-based microRNAs (miRNAs, miRs) in breast cancer (BC) patients a new field has been opened for circulating miRNAs as potential biomarkers in BC. In this pilot study, we evaluated to our knowledge for the first time whether dist...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383066/ https://www.ncbi.nlm.nih.gov/pubmed/25886191 http://dx.doi.org/10.1186/s12885-015-1190-4 |
_version_ | 1782364673177288704 |
---|---|
author | Erbes, Thalia Hirschfeld, Marc Rücker, Gerta Jaeger, Markus Boas, Jasmin Iborra, Severine Mayer, Sebastian Gitsch, Gerald Stickeler, Elmar |
author_facet | Erbes, Thalia Hirschfeld, Marc Rücker, Gerta Jaeger, Markus Boas, Jasmin Iborra, Severine Mayer, Sebastian Gitsch, Gerald Stickeler, Elmar |
author_sort | Erbes, Thalia |
collection | PubMed |
description | BACKGROUND: Since recent studies revealed the feasibility to detect blood-based microRNAs (miRNAs, miRs) in breast cancer (BC) patients a new field has been opened for circulating miRNAs as potential biomarkers in BC. In this pilot study, we evaluated to our knowledge for the first time whether distinct pattern of urinary miRNAs might be also applicable as innovative biomarkers for BC detection. METHODS: Urinary miRNA expression levels of nine BC-related miRNAs (miR-21, miR-34a, miR-125b, miR-155, miR-195, miR-200b, miR-200c, miR-375, miR-451) from 24 untreated, primary BC patients and 24 healthy controls were quantified by realtime-PCR. The receiver operating characteristic analyses (ROC) and logistic regression were calculated to assess discriminatory accuracy. RESULTS: Significant differences were found in the expression of four BC-associated miRNAs quantified as median miRNA expression levels. Urinary miR-155 levels were significantly higher in BC patients compared to healthy controls (1.49vs.0.25; p < 0.001). In contrast, compared to healthy controls, BC patients exhibited significantly lower urinary expression levels of miR-21 (2.27vs.5.07; p < 0.001), miR-125b (0.71vs.1.62; p < 0.001), and miR-451 (0.02vs.0.59 p = 0.004), respectively. The ROC including all miRNAs as well as the group of the four significant deregulated miRNAs separated BC patients from healthy controls with a very high (area under the receiver operating characteristic curve [AUC] = 0.932) and high accuracy (AUC = 0.887), respectively. CONCLUSIONS: We were able to demonstrate for the first time the feasibility to detect distinct BC-dependent urinary miRNA profiles. The expression levels of four urinary miRNAs were specifically altered in our cohort of BC patients compared to healthy controls. This distinct pattern offers the possibility for a specific discrimination between healthy women and primary BC patients. This sustains the potential role of urinary miRNAs as non-invasive innovative urine-based biomarkers for BC detection. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-1190-4) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4383066 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-43830662015-04-03 Feasibility of urinary microRNA detection in breast cancer patients and its potential as an innovative non-invasive biomarker Erbes, Thalia Hirschfeld, Marc Rücker, Gerta Jaeger, Markus Boas, Jasmin Iborra, Severine Mayer, Sebastian Gitsch, Gerald Stickeler, Elmar BMC Cancer Research Article BACKGROUND: Since recent studies revealed the feasibility to detect blood-based microRNAs (miRNAs, miRs) in breast cancer (BC) patients a new field has been opened for circulating miRNAs as potential biomarkers in BC. In this pilot study, we evaluated to our knowledge for the first time whether distinct pattern of urinary miRNAs might be also applicable as innovative biomarkers for BC detection. METHODS: Urinary miRNA expression levels of nine BC-related miRNAs (miR-21, miR-34a, miR-125b, miR-155, miR-195, miR-200b, miR-200c, miR-375, miR-451) from 24 untreated, primary BC patients and 24 healthy controls were quantified by realtime-PCR. The receiver operating characteristic analyses (ROC) and logistic regression were calculated to assess discriminatory accuracy. RESULTS: Significant differences were found in the expression of four BC-associated miRNAs quantified as median miRNA expression levels. Urinary miR-155 levels were significantly higher in BC patients compared to healthy controls (1.49vs.0.25; p < 0.001). In contrast, compared to healthy controls, BC patients exhibited significantly lower urinary expression levels of miR-21 (2.27vs.5.07; p < 0.001), miR-125b (0.71vs.1.62; p < 0.001), and miR-451 (0.02vs.0.59 p = 0.004), respectively. The ROC including all miRNAs as well as the group of the four significant deregulated miRNAs separated BC patients from healthy controls with a very high (area under the receiver operating characteristic curve [AUC] = 0.932) and high accuracy (AUC = 0.887), respectively. CONCLUSIONS: We were able to demonstrate for the first time the feasibility to detect distinct BC-dependent urinary miRNA profiles. The expression levels of four urinary miRNAs were specifically altered in our cohort of BC patients compared to healthy controls. This distinct pattern offers the possibility for a specific discrimination between healthy women and primary BC patients. This sustains the potential role of urinary miRNAs as non-invasive innovative urine-based biomarkers for BC detection. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12885-015-1190-4) contains supplementary material, which is available to authorized users. BioMed Central 2015-03-28 /pmc/articles/PMC4383066/ /pubmed/25886191 http://dx.doi.org/10.1186/s12885-015-1190-4 Text en © Erbes et al.; licensee BioMed Central. 2015 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Erbes, Thalia Hirschfeld, Marc Rücker, Gerta Jaeger, Markus Boas, Jasmin Iborra, Severine Mayer, Sebastian Gitsch, Gerald Stickeler, Elmar Feasibility of urinary microRNA detection in breast cancer patients and its potential as an innovative non-invasive biomarker |
title | Feasibility of urinary microRNA detection in breast cancer patients and its potential as an innovative non-invasive biomarker |
title_full | Feasibility of urinary microRNA detection in breast cancer patients and its potential as an innovative non-invasive biomarker |
title_fullStr | Feasibility of urinary microRNA detection in breast cancer patients and its potential as an innovative non-invasive biomarker |
title_full_unstemmed | Feasibility of urinary microRNA detection in breast cancer patients and its potential as an innovative non-invasive biomarker |
title_short | Feasibility of urinary microRNA detection in breast cancer patients and its potential as an innovative non-invasive biomarker |
title_sort | feasibility of urinary microrna detection in breast cancer patients and its potential as an innovative non-invasive biomarker |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383066/ https://www.ncbi.nlm.nih.gov/pubmed/25886191 http://dx.doi.org/10.1186/s12885-015-1190-4 |
work_keys_str_mv | AT erbesthalia feasibilityofurinarymicrornadetectioninbreastcancerpatientsanditspotentialasaninnovativenoninvasivebiomarker AT hirschfeldmarc feasibilityofurinarymicrornadetectioninbreastcancerpatientsanditspotentialasaninnovativenoninvasivebiomarker AT ruckergerta feasibilityofurinarymicrornadetectioninbreastcancerpatientsanditspotentialasaninnovativenoninvasivebiomarker AT jaegermarkus feasibilityofurinarymicrornadetectioninbreastcancerpatientsanditspotentialasaninnovativenoninvasivebiomarker AT boasjasmin feasibilityofurinarymicrornadetectioninbreastcancerpatientsanditspotentialasaninnovativenoninvasivebiomarker AT iborraseverine feasibilityofurinarymicrornadetectioninbreastcancerpatientsanditspotentialasaninnovativenoninvasivebiomarker AT mayersebastian feasibilityofurinarymicrornadetectioninbreastcancerpatientsanditspotentialasaninnovativenoninvasivebiomarker AT gitschgerald feasibilityofurinarymicrornadetectioninbreastcancerpatientsanditspotentialasaninnovativenoninvasivebiomarker AT stickelerelmar feasibilityofurinarymicrornadetectioninbreastcancerpatientsanditspotentialasaninnovativenoninvasivebiomarker |